•  
  •  
 

Mansoura Veterinary Medical Journal

Document Type

Original Article

Keywords

EA-ZnNPs; STZ; Diabetes; Heart; Liver

Abstract

Background:

Biochemical, molecular, and histopathological alterations are the most noticeable clinical and pathological characteristics attributed to diabetes mellitus. An imbalance in these parameters increases the risk of developing complications. Therefore, the main objective of this study was to determine the cardiac and hepatic protective effects of ellagic acid-loaded zinc nanoparticles (EA-ZnNPs) on diabetes, which were evaluated biochemically, molecularly, and histopathologically.

Methods: Four groups of 40 adult male rats were established in this study. The groups were subsequently classified as control, streptozotocin (STZ) diabetic, STZ treated with ellagic acid-loaded zinc nanoparticles (EA-ZnNPs), and STZ treated with insulin. After six weeks of treatment, blood, heart, and liver tissue samples were obtained, and biochemical, molecular, and histopathological examination were performed.

Results:

Treatment with EA-ZnNPs or insulin had significant consequences, as evidenced by the restoration of cardiac and hepatic damage, as well as a substantial reduction in the serum levels of heart and liver-related parameters, such as triglycerides, serum cholesterol, creatine kinase MB isoenzyme (CK-

MB), lactate dehydrogenase (LDH), ALT, AST, cardiac and hepatic malondialdehyde (MDA), glutathione peroxidase (GPx), catalase, and inflammatory indices. Additionally, there were notable histological changes in the hepatic histoarchitecture of diabetic rats treated with EA-ZnNPs.

Conclusion:

EA-ZnNPs could serve to preserve the liver and cardiac tissue in rats with diabetes.

Receive Date

Mar 11, 2024

Accept Date

Sep 4, 2024

Publication Date

2024

Share

COinS